• Daniel K Benjamin, Mark L Hudak, Shahnaz Duara, David A Randolph, Margarita Bidegain, Gratias T Mundakel, Girija Natarajan, David J Burchfield, Robert D White, Karen E Shattuck, Natalie Neu, Catherine M Bendel, M Roger Kim, Neil N Finer, Dan L Stewart, Antonio C Arrieta, Kelly C Wade, David A Kaufman, Paolo Manzoni, Kristi O Prather, Daniela Testoni, Katherine Y Berezny, P Brian Smith, and Fluconazole Prophylaxis Study Team.
• Duke Clinical Research Institute, Durham, North Carolina.
• JAMA. 2014 May 7; 311 (17): 174217491742-9.

ImportanceInvasive candidiasis in premature infants causes death and neurodevelopmental impairment. Fluconazole prophylaxis reduces candidiasis, but its effect on mortality and the safety of fluconazole are unknown.ObjectiveTo evaluate the efficacy and safety of fluconazole in preventing death or invasive candidiasis in extremely low-birth-weight infants.Design, Setting, And PatientsThis study was a randomized, blinded, placebo-controlled trial of fluconazole in premature infants. Infants weighing less than 750 g at birth (N = 361) from 32 neonatal intensive care units (NICUs) in the United States were randomly assigned to receive either fluconazole or placebo twice weekly for 42 days. Surviving infants were evaluated at 18 to 22 months corrected age for neurodevelopmental outcomes. The study was conducted between November 2008 and February 2013.InterventionsFluconazole (6 mg/kg of body weight) or placebo.Main Outcomes And MeasuresThe primary end point was a composite of death or definite or probable invasive candidiasis prior to study day 49 (1 week after completion of study drug). Secondary and safety outcomes included invasive candidiasis, liver function, bacterial infection, length of stay, intracranial hemorrhage, periventricular leukomalacia, chronic lung disease, patent ductus arteriosus requiring surgery, retinopathy of prematurity requiring surgery, necrotizing enterocolitis, spontaneous intestinal perforation, and neurodevelopmental outcomes-defined as a Bayley-III cognition composite score of less than 70, blindness, deafness, or cerebral palsy at 18 to 22 months corrected age.ResultsAmong infants receiving fluconazole, the composite primary end point of death or invasive candidiasis was 16% (95% CI, 11%-22%) vs 21% in the placebo group (95% CI, 15%-28%; odds ratio, 0.73 [95% CI, 0.43-1.23]; P = .24; treatment difference, -5% [95% CI, -13% to 3%]). Invasive candidiasis occurred less frequently in the fluconazole group (3% [95% CI, 1%-6%]) vs the placebo group (9% [95% CI, 5%-14%]; P = .02; treatment difference, -6% [95% CI, -11% to -1%]). The cumulative incidences of other secondary outcomes were not statistically different between groups. Neurodevelopmental impairment did not differ between the groups (fluconazole, 31% [95% CI, 21%-41%] vs placebo, 27% [95% CI, 18%-37%]; P = .60; treatment difference, 4% [95% CI, -10% to 17%]).Conclusions And RelevanceAmong infants with a birth weight of less than 750 g, 42 days of fluconazole prophylaxis compared with placebo did not result in a lower incidence of the composite of death or invasive candidiasis. These findings do not support the universal use of prophylactic fluconazole in extremely low-birth-weight infants.Trial Registrationclinicaltrials.gov Identifier: NCT00734539.

22 keywords...

hide…